Skip to main content
C

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,504 across all filing types
Latest filing 2025-10-17 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY
Transaction in Own Shares Classification · 1% confidence The document is a voluntary announcement on the on-market purchase of the company’s own shares under its share award scheme. It details the number of shares repurchased, average price, total consideration, and trustee holdings. This clearly constitutes a report of the company buying back its own shares. Therefore, it falls under 'Transaction in Own Shares' (POS).
2025-10-17 English
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY
Transaction in Own Shares Classification · 1% confidence The document is a Hong Kong Exchange voluntary announcement by CSPC Pharmaceutical Group Limited detailing the on-market repurchase of its own shares by the Trustee under its restricted share award scheme. It provides numbers of shares purchased, average price, total consideration, and remaining balance. This is a report of a share buy-back (transaction in own shares), matching the definition of code POS.
2025-10-16 English
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY
Transaction in Own Shares Classification · 1% confidence The document is a company announcement detailing the on-market purchase of its own shares by a trustee under its share award scheme, specifying number of shares bought, price, and remaining balance. This falls under “Transaction in Own Shares” (POS). It is neither a general regulatory filing nor a full report, but specifically reports a share repurchase.
2025-10-15 English
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY
Transaction in Own Shares Classification · 1% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited detailing an on-market purchase of its own shares under its share award scheme. This is a report of a company buying back its own shares, which falls squarely under the 'Transaction in Own Shares' category (Code: POS).
2025-10-14 English
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY
Transaction in Own Shares Classification · 1% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding an on-market purchase of shares under its share award scheme, detailing the number of shares repurchased, price, and Trustee holding balance. This corresponds to a transaction where the company (through its Trustee) buys back its own shares. Under the classification definitions, this falls squarely under “Transaction in Own Shares” (Code: POS).
2025-10-13 English
VOLUNTARY ANNOUNCEMENT - TACROLIMUS EXTENDED-RELEASE CAPSULES OBTAIN DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding regulatory approval of a drug product by the National Medical Products Administration of China. It does not report financial results, management changes, dividends, share issues, or any of the specific categories like 10-K, IR, ER, etc. Instead, it is an operational/regulatory update that does not fit any more specific filing type. According to the definitions, this falls under the fallback category “Regulatory Filings” (RNS).
2025-10-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.